Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Losartan for Renal Protection in Renal Transplant Patients
NCT00140907Phase 4
Key facts
- Status
- Completed
- Start
- Mar 2000
- Primary completion
- Jan 2005
- Sponsor
- Organon & Co.
- Modality
- Small Molecules
- Drugs
- losartan
- Conditions
- Chronic Allograft Kidney Disease (CKaD)
01
Overview
Phase 4, randomised, double-blind trial in Chronic Allograft Kidney Disease (CKaD) comparing Placebo with Losartan (2 arms). Primary endpoint: Incidence of chronic allograft nephropathy at 24 months. Started Mar 2000; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Placebo
Placebo 25mg titrated to 50mg daily
Losartan
Losartan 25mg titrated to 50mg daily
03
Who it enrols
Renal transplant recipients (4-8 weeks post-transplant) with stable serum creatinine and controlled blood pressure, excluding those with severe rejection, heart failure, or liver disease.
04
Endpoints
Primary
Incidence of chronic allograft nephropathy
Beyond the preview
Go deeper on NCT00140907.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00140907.